the Sarepta chart shows that investors are disappointed that the FDA only gave Sareptas drug 901 partial approval
Also in the first 1/4 2024 Sarepta has to prove efficacy on 901 …
Let’s hope Gil Price can inform the PPMDaudience that ANP iOS a serious contender for the DMD crown.
the Sarepta chart shows that investors are disappointed that the...
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $94.66M | |||
| Open | High | Low | Value | Volume |
| 10.5¢ | 10.5¢ | 10.5¢ | $5.7K | 54.28K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 178869 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 138249 | 3 |
View Market Depth
| Last trade - 13.03pm 08/10/2024 (20 minute delay) ? |
| PER (ASX) Chart |